
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') announces today it has entered into an exclusive distribution agreement with Fleurus-based IRE Elit S.A. ('IRE ELiT') to distribute Telix's prostate cancer imaging product TLX591-CDx (⁶⁸Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.

Under the terms of the agreement, IRE has been appointed as the exclusive commercial distributor of TLX591-CDx in France and French overseas territories, during both the initial period of 'autorisation d'exploitation temporaire' (temporary authorisation) and once full European marketing authorisation is granted, which is anticipated to occur in 2021.

IRE ELiT CEO Erich Kollegger stated "Our distribution agreement with Telix will enable IRE ELiT to bring an important new diagnostic imaging product, which is a highly synergistic product with our ⁶⁸Ga generator, to the prostate cancer market in France and its overseas territories. The increased diagnostic information that this product will provide French clinicians managing patients with prostate cancer truly aligns with IRE ELiT's stated mission of helping patients to remain healthy."

Telix Europe President & Chief Operating Officer Ludovic Wouters stated "We are pleased to have entered this master distribution agreement with IRE ELiT so that together we will be able to bring this highly anticipated prostate imaging agent to French patients. IRE ELiT has a well-deserved reputation as a leader in the radiopharmaceutical industry in Europe and as a provider of products of outstanding quality."

About TLX591-CDx

TLX591-CDx (kit for the preparation of ⁶⁸Ga-PSMA-11) is a proprietary formulation of PSMA-HBED-CC (PSMA-11), a novel small molecule agent targeting prostate-specific membrane antigen (PSMA), originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).¹ The 'cold kit' format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, ideally suited for the radiopharmacy setting. TLX591-CDx has not received a marketing authorisation in any European Union country.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, renal and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

¹ Eder, et al. *Bioconjugate Chem* Apr 18, 2012; 23(4): 688-97.

About IRE ELIT

IRE ELiT is a radiopharmaceutical company and the innovation subsidiary of IRE, which was founded in 2010 in order to develop radiopharmaceuticals used in molecular imaging and therapy. IRE ELiT works closely with its clients in a 'test & learn' spirit as well as with globally recognised universities and research centres. Today, IRE ELiT is a significant global supplier of germanium-68 (Ge-68) / gallium-68 (Ga-68) generators, which have been approved for use as a drug in Europe and as an active pharmaceutical ingredient (API) in the USA. IRE and IRE ELiT currently employ 230 people. For more information visit www.ire.eu.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.